Advertisement
U.S. markets close in 1 hour 52 minutes

Provectus Biopharmaceuticals, Inc. (PVCT)

Other OTC - Other OTC Delayed Price. Currency in USD
0.1899-0.0101 (-5.31%)
As of 01:45PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2000
Open0.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1771 - 0.2000
52 Week Range0.0560 - 0.2250
Volume212,787
Avg. Volume314,370
Market Cap79.667M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for PVCT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PROVECTUS BIOPHARMACEUTICALS IN
    NKTR: Lowering target price to $0.63NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.632000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Insider Monkey

    Provectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call Transcript

    Provectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call Transcript February 22, 2024 Provectus Biopharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. This is the conference operator. Welcome to the Provectus Biopharmaceuticals First Quarter […]